Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

Data ReadoutpositiveAnti-IL-23 AntibodyPositive

AI Analysis

Summary

Spyre's Anti-IL-23 Antibody met its primary endpoint in an Ulcerative Colitis clinical trial. The positive trial result represents a meaningful advancement in the company's pipeline for inflammatory bowel disease.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Anti-IL-23 Antibody met primary goal in Ulcerative Colitis study

Importance:7/10

Sentiment:

0.80

Phase 2Ulcerative ColitisImmunologyPositive Data

Related Companies

$SYRE

Read the original article

Published by yahoo_finance on September 9, 2026 1:56 PM

Read Original